American College of Clinical Pharmacy
      Search      Cart
         

SCHEDULE

Clinical Reasoning Series in Pharmacotherapy — Part One

Tuesday, October 15, 2024 from 8:30 AM to 11:45 AM MST at Convention Center North Building / Meeting Room 121

The Clinical Reasoning Series aims to deliver programs that will meaningfully contribute to advancing pharmacy specialists’ knowledge, skills, and clinical judgment. Topic selection for the program reflects content that is timely and of relevance and value to the practice of Board Pharmacotherapy Specialists (BCPS).

Participants will have the opportunity to attend four educational activities, broken into a two-part morning and a two-part afternoon session. Part One will offer 3.0 contact hours of continuing pharmacy education credit toward BCPS recertification credit upon completing the required posttests by the submission deadline and achieving a predetermined passing score. The posttests will be available on November 6, 2024. The deadline to submit posttests and earn recertification credit for the session will be November 6, 2025. If you have not already purchased posttest access and wish to add it to your registration, email [email protected] or visit the registration desk on or before October 15, 2024.

Kathleen Pincus, Pharm.D., BCACP, BCPS
Moderator:Kathleen Pincus, Pharm.D., BCACP, BCPS

Associate Professor & PGY-2 Ambulatory Care Residency Program Director
University of Maryland School of Pharmacy
Baltimore, MD

  View Biography

Contemporary Weight Management — The Pharmacist’s Role

8:30 AM to 10:00 AM
Available for 1.50 hours of CPE credit
Activity Number: 0217-0000-24-157-L01-P
Activity Type: An Application-Based Activity

​Contemporary weight management will discuss the pharmacist’s role in contemporary care for patients with obesity. This presentation will review recent updates in treatment modalities, evidence supporting therapeutic effects, and clinical practice guidelines for weight management, including discussions of pharmacotherapeutic product selection, monitoring, management of adverse drug effects, and considerations for patients receiving bariatric surgeries. Interprofessional collaboration, including interfacing with nutritionists and other specialists, will also be discussed. This activity offers 1.5 contact hours of CPE and/or BCPS recertification credit. 

Learning Objectives

1. Compare currently available pharmacological agents used in the treatment of obesity.  

2. Assess current guidelines in the management of obesity.

3. Evaluate the cardiovascular benefits of obesity pharmacotherapy and bariatric interventions.

4. Review the most commonly employed bariatric interventions and their impact on pharmacotherapy in patients with obesity.

5. Distinguish the roles of the interprofessional healthcare team in obesity management.

6. Examine possible new agents or therapeutic options in the management of obesity.

Brian K. Irons, Pharm.D., FCCP, BCACP
Speaker:Brian K. Irons, Pharm.D., FCCP, BCACP
Professor
Texas Tech University Health Science Center Jerry H. Hodge School of Pharmacy
Lubbock, Texas
  View Biography

Break in Programming

10:00 AM to 10:15 AM

​New Considerations in Diabetes Management: The Role of Continuous Glucose Monitors & The Risk of Euglycemic Diabetic Ketoacidosis (eDKA) ​

10:15 AM to 11:45 AM
Available for 1.50 hours of CPE credit
Activity Number: 0217-0000-24-156-L01-P
Activity Type: An Application-Based Activity

New Considerations in Diabetes Management will focus on advancements in care for patients with diabetes that have emerged in recent years. This presentation will cover the emerging role of continuous glucose monitoring with a focus on its clinical benefits and potential barriers in access. Participants will be given the opportunity to design a treatment regimen based on CGM data in a patient case. Additionally, the identification and management of euglycemic diabetic ketoacidosis (eDKA), a more commonly recognized adverse effect to an often used antihyperglycemic, sodium-glucose co-transport (SGLT2) inhibitors, will be discussed. Participants will be able to distinguish eDKA from DKA in regards to diagnosis, as well as highlight the differences in management. This activity offers 1.5 contact hours of CPE and/or BCPS recertification credit. 

Learning Objectives

1. ​Analyze data showing the clinical benefits of continuous glucose monitors (CGMs).

2. ​Investigate barriers to CGM access in patients with diabetes.

3. Design an evidence-based treatment regimen for a patient with diabetes based on their ambulatory glucose profile.

4. ​​Given a patient case, identify risk factors for developing eDKA.

5. Distinguish between the characteristics of patients presenting with diabetic ketoacidosis (DKA) and euglycemic DKA (eDKA).

6. ​​Examine treatment standards for patients with eDKA.​

7. ​​Differentiate between the management of eDKA and DKA in patients with diabetes.​

Ebony I. Evans, Pharm.D.
Speaker:Ebony I. Evans, Pharm.D.

Clinical Assistant Professor of Pharmacy Practice and Ambulatory Care Pharmacist
Howard University College of Pharmacy​
Washington, D.C.

  View Biography

Cookies

This website uses cookies to help ACCP provide you with the best user experience. If you continue to use our services, ACCP will assume that you agree to the use of such cookies. You can find out how to update your settings by referring to ACCP’s Policy on Cookies.